(Q28288711)

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Hepatic encephalopathy: molecular mechanisms underlying the clinical syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Novel mechanisms of action of three antiepileptic drugs, vigabatrin, tiagabine, and topiramate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Topiramate protects against glutamate- and kainate-induced neurotoxicity in primary neuronal–astroglial cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Brain uptake of glutamate: food for thought

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Biological differences between ischemia, hypoglycemia, and epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Excitatory amino acids in cerebrospinal fluid following traumatic brain injury in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Promising strategies to minimize secondary brain injury after head trauma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Suppression of epileptogenesis by modification of N-methyl-D-aspartate receptor subunit composition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Clinical significance of CSF glutamate concentrations following severe traumatic brain injury in humans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Evidence for prolonged release of excitatory amino acids in severe human head trauma. Relationship to clinical events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Factors affecting excitatory amino acid release following severe human head injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Neurotransmitter dysfunction in hepatic encephalopathy: new approaches and new findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Ionotropic glutamate receptors: still a target for neuroprotection in brain ischemia? Insights from in vitro studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Evidence for an astrocytic glutamate transporter deficit in hepatic encephalopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Cell-selective effects of ammonia on glutamate transporter and receptor function in the mammalian brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Effects of ammonia on glutamate transporter (GLAST) protein and mRNA in cultured rat cortical astrocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

7 January 2021

Glutamate and epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Astrocytes and brain injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Compartmentation of brain glutamate metabolism in neurons and glia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Extracellular brain glutamate during acute liver failure and during acute hyperammonemia simulating acute liver failure: an experimental study based on in vivo brain dialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

The roles of metabotropic glutamate receptors in seizures and epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Neuroprotective activity of metabotropic glutamate receptor ligands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Neuroprotection, excitotoxicity and NMDA antagonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

CGS-19755, a competitive NMDA receptor antagonist, reduces calcium-calmodulin binding and improves outcome after global cerebral ischemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Hepatic encephalopathy: An update of pathophysiologic mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

7 January 2021

Neurology and the liver

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Age-specific N-methyl-D-aspartate-induced seizures: perspectives for the West syndrome model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Dexanabinol (HU-211) in the treatment of severe closed head injury: a randomized, placebo-controlled, phase II clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Effect of anticonvulsant drugs on glutamate neurotoxicity in cortical cell culture.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

L-glutamate and gamma-aminobutyric acid uptake in synaptosomes from the cerebral cortex of dogs with congenital chronic hepatic encephalopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

N-methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Cellular and molecular basis of epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Glutamate as a neurotransmitter in the brain: review of physiology and pathology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Glutamate receptors and transporters in genetic and acquired models of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Glutamate metabotropic receptors as targets for drug therapy in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Astroglial dysfunction in hepatic encephalopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Chronic and acute compressive spinal cord lesions in dogs due to intervertebral disc herniation are associated with elevation in lumbar cerebrospinal fluid glutamate concentration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Alteration in extracellular amino acids after traumatic spinal cord injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

NPY inhibits glutamatergic excitation in the epileptic human dentate gyrus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

GABA and glutamate in the human brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

The metabotropic glutamate receptors: structure, activation mechanism and pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Low concentrations of cerebrospinal fluid GABA correlate to a reduced response to phenobarbital therapy in primary canine epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Channel gating of NMDA receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

NMDA receptor activation during status epilepticus is required for the development of epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Glutamate release in severe brain ischaemia is mainly by reversed uptake.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Group I metabotropic glutamate receptor activation produces prolonged epileptiform neuronal synchronization and alters evoked population responses in the hippocampus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Protective effect of MK801 in experimental brain injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Transport of glutamate and other amino acids at the blood-brain barrier

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

II. Glutamine and glutamate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Excitatory amino acid agonists and antagonists: pharmacology and therapeutic applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Glutamatergic mechanisms in different disease states: overview and therapeutical implications -- an introduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Modulatory role of neuropeptides in seizures induced in rats by stimulation of glutamate receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Comparison of the neuroprotective effects of the N-methyl-D-aspartate antagonist MK-801 and the opiate-receptor antagonist nalmefene in experimental spinal cord ischemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Neuronal apoptosis after CNS injury: the roles of glutamate and calcium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

The effect of groups II and III metabotropic glutamate receptor activation on neuronal injury in a rodent model of traumatic brain injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Reduced expression of astrocytic glycine transporter (Glyt-1) in acute liver failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007

Glutamate receptors in epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TVJL.2005.11.007